On September 26, 2025, PepGen Inc. released data from the 15 mg/kg cohort of its FREEDOM‑DM1 Phase 1 single‑ascending‑dose study, reporting a mean splicing correction of 53.7 % measured by a 22‑gene panel at 28 days post‑dosing. All six patients in the cohort responded, and the study showed no serious treatment‑related adverse events; only mild or moderate events were observed, with a single transient kidney biomarker elevation that resolved without intervention.
The 15 mg/kg data represent the highest splicing correction reported in myotonic dystrophy type 1 patients to date and confirm the dose‑proportional increase observed in earlier 5 mg/kg (12.3 %) and 10 mg/kg (29.1 %) cohorts. The results reinforce PepGen’s Enhanced Delivery Oligonucleotide platform as a promising therapeutic approach for DM1 and provide a critical milestone for the company’s clinical development program.
On the same day, PepGen priced a public offering of 31,250,000 shares of its common stock at $3.20 per share, an underwritten offering that is expected to generate $100 million in gross proceeds. The capital raise is intended to support ongoing clinical studies and address the company’s liquidity needs amid a cash runway that extends into the second quarter of 2026.
Together, the record clinical data and the equity offering represent significant, material events that directly influence PepGen’s development trajectory and financial position, warranting coverage as a newsworthy development for investors and stakeholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.